# Samsara BioCapital

> Samsara BioCapital is a VC fund backing Biotechnology and Health Care. See 184 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Palo Alto, United States
- Total investments: 184
- Last investment: Jul 2026
- Lead investor: 16%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/samsara-biocapital/
- X (Twitter): https://twitter.com/samsaracapital
- Website: http://www.samsaracap.com/

Samsara BioCapital is a VC fund in Palo Alto focused on Biotechnology and Health Care. Samsara Biocapital provides investment advisory services to help entrepreneurs turn their own ideas and visions into successful companies. Samsara BioCapital, as a results-driven organization, is always looking for ambitious and visionary partners with the drive and flexibility to take their company to the next level. Samsara BioCapital promotesbiotech innovation and collaborates with inspiring companies as they develop important and innovative new therapies.

## Contacts

5 contacts available for Samsara BioCapital. Shizune tracks 7 team members at Samsara BioCapital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/samsara-biocapital?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $40M–$200M |
| Series B | $35M–$170M |
| Post-IPO Equity | $40M–$200M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 104 | 57% |
| Health Care | 55 | 30% |
| Therapeutics | 45 | 24% |
| Pharmaceutical | 36 | 20% |
| Medical | 34 | 18% |

26 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 44 | 24% |
| Series A | 32 | 17% |
| Post-IPO Equity | 29 | 16% |
| Series C | 18 | 10% |
| Series D | 7 | 4% |

9 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 92 | 50% |
| United Kingdom | 5 | 3% |
| Canada | 4 | 2% |
| China | 2 | 1% |
| France | 1 | 1% |

11 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Abraham Bassan | Partner | 5 | https://shizune.co/investors/profile/abraham-bassan |
| Michael Dybbs | Partner | 13 | https://shizune.co/investors/profile/mike-dybbs |
| Christian Richard | Head of Public Research | 0 | https://shizune.co/investors/profile/christian-m-richard |
| Marcos Milla | Venture Partner | 5 | https://shizune.co/investors/profile/marcos-milla |
| Srini Akkaraju | Founder | 6 | https://shizune.co/investors/profile/srini-akkaraju |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Claris Biotherapeutics | Claris Biotherapeutics develops a topical formulation intended to cure corneal wounds, ulcers, and scars. The formulation creates a recombinant hepatocyte growth factor which accelerates the healing process, providing healthcare providers noninvasive therapeutic treatment. | $118M | Series B | Jul 28, 2026 |  |
| Nura Bio | Nura Bio revolutionizes the treatment of neurological diseases with novel, life-changing neuroprotective medicines. Nura Bio was conceived in 2018 by The Column Group and its scientific founders. | $73.8M | Series B | Jun 22, 2026 |  |
| Memento Medicines | Memento Medicines is a biotechnology company focused on the development of novel antibody therapies for ophthalmology. The company's core business model centers on licensing and advancing specialized, multi-target biologics to address high-demand clinical needs in the retinal disease landscape. Its primary value proposition rests on its leadprogram, MMT-205, a dual-action bispecific antibody engineered to simultaneously activate Tie2 receptors and inhibit VEGF. This therapeutic candidate is being clinical developed to improve treatment durability and visual outcomes for individuals suffering from neovascular age-related macular degeneration and diabetic macular edema. | $93M | Series A | Jun 18, 2026 |  |
| Inventiva Pharma | Inventiva Pharma is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders and oncology.They have built a pipeline backed by a discovery engine with an extensive library ofproprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging these assets and expertise, they are advancing two clinical candidates in three indications, as well as a deep pipeline of earlier stage programs. | $120M | Post-IPO Equity | Jun 02, 2026 |  |
| Artiva Biotherapeutics | Artiva Biotherapeutics is a private biotech company advancing a pipeline of off-the-shelf, allogeneic NK cell therapies, for the treatment of hematologic cancers or solid tumors. It was founded on the understanding that NK cells hold enormous therapeutic potential as cancer therapies and the dedication and expertise to overcome technologicalbarriers in the scaling and manufacturing of these cells. At Artiva, its mission is to deliver highly effective cell therapies that are also safe and immediately available and accessible to any cancer patient who stands to benefit. Artiva’s platform delivers scalability, quality, and cryopreservation to support a pipeline of safe, effective, versatile, and accessible product candidates. | $300M | Post-IPO Equity | May 08, 2026 |  |
| Valneva | Valneva is a pharmaceutical company developing prophylactic vaccines to treat infectious diseases. The company focused on developing and commercializing prophylactic vaccines for infectious diseases with significant unmet medical needs. Valneva has leveraged its expertise and capabilities both to commercialize two vaccines successfully and torapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus, and COVID-19. | $43.1M | Post-IPO Equity | Apr 30, 2026 |  |
| Coultreon Biopharma | Coultreon Biopharma is developing best-in-class therapeutics that target clinically validated pathways in immunology and metabolic illnesses.Coultreon Biopharma employs extensive experience in disease biology, drug development, and translational science to identify the optimum treatment approach for addressing underlying illness biology withbest-in-class therapeutics. | $125M | Series A | Apr 28, 2026 |  |
| Sidewinder Therapeutics | Sidewinder Therapeutics develops bispecific antibody-drug conjugates (ADCs) aimed at treating solid tumors. Their mission is to create life-saving therapies through precision therapeutics. | $137M | Series B | Apr 08, 2026 |  |
| Ambrosia Biosciences | Ambrosia Biosciences offers drug development services for small molecule-based therapies for obesity and other metabolic disorders. | $100M | Series B | Mar 31, 2026 |  |
| Sutro Biopharma | Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF.Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. | $110M | Post-IPO Equity | Feb 10, 2026 |  |

10 of 184 investments shown.

## Co-investors
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 41 deals together
- [EcoR1 Capital](https://shizune.co/investors/profile/ecor1-capital) — VC Fund, 28 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 27 deals together
- [Surveyor Capital](https://shizune.co/investors/profile/surveyor-capital) — VC Fund, 26 deals together
- [Invus](https://shizune.co/investors/profile/invus) — VC Fund, 25 deals together
- [Janus Henderson Investors](https://shizune.co/investors/profile/janus-henderson-investors) — VC Fund, 25 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [PMV](https://shizune.co/investors/profile/pmv-eu) — VC Fund
- [Limburgse Reconversie Maatschappij](https://shizune.co/investors/profile/limburgse-reconversie-maatschappij) — VC Fund
- [Qbic Fund](https://shizune.co/investors/profile/qbic-fund) — VC Fund

## Featured in investor lists
- [Biotech Investors in United States](https://shizune.co/investors/biotech-investors-united-states)
- [Biotech VC Funds in United States](https://shizune.co/investors/biotech-vc-funds-united-states)
- [Life Science VC Funds in Belgium](https://shizune.co/investors/life-science-vc-funds-belgium)
- [Life Science Investors in Belgium](https://shizune.co/investors/life-science-investors-belgium)
- [Medical Device VC Funds in Belgium](https://shizune.co/investors/medical-device-vc-funds-belgium)

## FAQ

### What does Samsara BioCapital invest in?

Samsara BioCapital invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series A stage. Most of the 184 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Samsara BioCapital's check size?

Samsara BioCapital typically joins rounds of $40M–$200M at Series A, $35M–$170M at Series B and $40M–$200M at Post-IPO Equity. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Samsara BioCapital participates in.

### How do I contact Samsara BioCapital?

Public channels for Samsara BioCapital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Samsara BioCapital?

The team at Samsara BioCapital includes Abraham Bassan (Partner), Michael Dybbs (Partner) and Christian Richard (Head of Public Research), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co